Title |
FOXFIRE protocol: an open-label, randomised, phase III trial of 5-fluorouracil, oxaliplatin and folinic acid (OxMdG) with or without interventional Selective Internal Radiation Therapy (SIRT) as first-line treatment for patients with unresectable liver-only or liver-dominant metastatic colorectal cancer
|
---|---|
Published in |
BMC Cancer, July 2014
|
DOI | 10.1186/1471-2407-14-497 |
Pubmed ID | |
Authors |
Susan J Dutton, Nicola Kenealy, Sharon B Love, Harpreet S Wasan, Ricky A Sharma |
Abstract |
Colorectal cancer (CRC) is the second most common malignancy in Europe and a leading cause of cancer-related death. Almost 50% of patients with CRC develop liver metastases, which heralds a poor prognosis unless metastases can be downsized to surgical resection or ablation. The FOXFIRE trial examines the hypothesis that combining radiosensitising chemotherapy (OxMdG: oxaliplatin, 5-fluorouracil and folic acid) with Selective Internal Radiation Therapy (SIRT or radioembolisation) using yttrium-90 resin microspheres (SIR-Spheres®; Sirtex Medical Limited, North Sydney, Australia) as a first-line treatment for liver-dominant metastatic CRC will improve clinical outcomes when compared to OxMdG chemotherapy alone. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
India | 1 | 50% |
Unknown | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Brazil | 2 | 2% |
Unknown | 131 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 19 | 14% |
Researcher | 17 | 13% |
Student > Ph. D. Student | 15 | 11% |
Other | 13 | 10% |
Student > Bachelor | 10 | 8% |
Other | 26 | 20% |
Unknown | 33 | 25% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 55 | 41% |
Nursing and Health Professions | 12 | 9% |
Social Sciences | 5 | 4% |
Agricultural and Biological Sciences | 4 | 3% |
Biochemistry, Genetics and Molecular Biology | 3 | 2% |
Other | 17 | 13% |
Unknown | 37 | 28% |